| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Journal Article |
Department of Human Genetics, Flanders Interuniversity Institute for Biotechnology (VIB), University of Leuven, Leuven, Belgium.
Over the past 20 years, a large number of genes involved in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) has been identified by molecular characterization of recurrent chromosomal aberrations and more subtle genetic defects. When reviewing the current list of oncogenes and tumor suppressor genes, it becomes clear that these can be grouped into four classes of mutations, which are involved in: (i) cell cycle deregulation; (ii) impaired differentiation; (iii) proliferation and survival advantage and (iv) unlimited self-renewal capacity. Based on recent studies of T-ALL, we can speculate that at least these four different mutations are required for the development of T-ALL. In this review we summarize our current insights into the molecular pathogenesis of T-ALL, and we discuss how these molecular findings provide new directions for future research and novel therapeutic strategies in T-ALL.
This article has been cited by other articles:
|
|
 |
|
  P. Ballerini, J. Landman-Parker, J. M. Cayuela, V. Asnafi, M. Labopin, V. Gandemer, Y. Perel, G. Michel, T. Leblanc, C. Schmitt, et al. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome Haematologica, November 1, 2008; 93(11): 1658 - 1665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Van Vlierberghe, M. van Grotel, J. Tchinda, C. Lee, H. B. Beverloo, P. J. van der Spek, A. Stubbs, J. Cools, K. Nagata, M. Fornerod, et al. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia Blood, May 1, 2008; 111(9): 4668 - 4680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. V. Balgobind, P. Van Vlierberghe, A. M. W. van den Ouweland, H. B. Beverloo, J. N. R. Terlouw-Kromosoeto, E. R. van Wering, D. Reinhardt, M. Horstmann, G. J. L. Kaspers, R. Pieters, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis Blood, April 15, 2008; 111(8): 4322 - 4328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J.T. Staal and A. W. Langerak Signaling pathways involved in the development of T-cell acute lymphoblastic leukemia Haematologica, April 1, 2008; 93(4): 493 - 497. [Full Text] [PDF]
|
|
|
|
|
|
K. De Keersmaecker, I. Lahortiga, N. Mentens, C. Folens, L. Van Neste, S. Bekaert, P. Vandenberghe, M. D. Odero, P. Marynen, and J. Cools In vitro validation of {gamma}-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia Haematologica, April 1, 2008; 93(4): 533 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Dik, B. Nadel, G. K. Przybylski, V. Asnafi, P. Grabarczyk, J. M. Navarro, B. Verhaaf, C. A. Schmidt, E. A. Macintyre, J. J. M. van Dongen, et al. Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL Blood, July 1, 2007; 110(1): 388 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chiaretti, S. Tavolaro, E. M. Ghia, C. Ariola, C. Matteucci, L. Elia, R. Maggio, M. Messina, M. R. Ricciardi, A. Vitale, et al. Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis Haematologica, May 1, 2007; 92(5): 619 - 626. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
